Literature DB >> 9918562

SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.

M Portier1, M Rinaldi-Carmona, F Pecceu, T Combes, C Poinot-Chazel, B Calandra, F Barth, G le Fur, P Casellas.   

Abstract

In the present report, we investigated in detail the effects of SR 144528, a selective antagonist of the peripheral cannabinoid receptor (CB2), on two well-characterized functions mediated by CB2: the induction of the early response gene krox24 and the inhibition of adenylyl cyclase. We generated Chinese hamster ovary cells doubly transfected with human CB2 and a luciferase reporter gene linked to either the murine krox24 regulatory sequence or multiple cAMP responsive elements. Our results show that (1) SR 144528 antagonizes the effect of receptor agonists-it inhibits the krox24 reporter activity and prevents the inhibition of forskolin-induced cAMP reporter activity mediated by CP 55,940; (2) CB2 is autoactivated-CB2 mediates signaling in the absence of ligand, and this basal activity is reduced by pretreating the cells with pertussis toxin; (3) SR 144528 is an inverse agonist-it reproduces the effects of pertussis toxin; and (4) inhibition of precoupled CB2 by a long-term pretreatment of cells with SR 144528 potentiates krox24 response to cannabinoid receptor agonists and restores activation of adenylyl cyclase. Taken together, these data provide evidences for the inverse agonist property of SR 144528 and the constitutive activation of CB2 in Chinese hamster ovary-expressing cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918562

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

Authors:  Richard W Mercier; Ying Pei; Lakshmipathi Pandarinathan; David R Janero; Jing Zhang; Alexandros Makriyannis
Journal:  Chem Biol       Date:  2010-10-29

Review 2.  CB2 receptors as new therapeutic targets for liver diseases.

Authors:  S Lotersztajn; F Teixeira-Clerc; B Julien; V Deveaux; Y Ichigotani; S Manin; J Tran-Van-Nhieu; M Karsak; A Zimmer; A Mallat
Journal:  Br J Pharmacol       Date:  2007-10-22       Impact factor: 8.739

3.  Modulation of constitutive activity and signaling bias of the ghrelin receptor by conformational constraint in the second extracellular loop.

Authors:  Jacek Mokrosiński; Thomas M Frimurer; Bjørn Sivertsen; Thue W Schwartz; Birgitte Holst
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

4.  The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors.

Authors:  Alexandre A Steiner; Alla Y Molchanova; M Devrim Dogan; Shreya Patel; Erika Pétervári; Márta Balaskó; Samuel P Wanner; Justin Eales; Daniela L Oliveira; Narender R Gavva; M Camila Almeida; Miklós Székely; Andrej A Romanovsky
Journal:  J Physiol       Date:  2011-03-14       Impact factor: 5.182

5.  Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Exp Neurol       Date:  2006-10-11       Impact factor: 5.330

6.  Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Authors:  A Thomas; G L Baillie; A M Phillips; R K Razdan; R A Ross; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

7.  Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.

Authors:  Yuxun Zhang; Zhaojun Xie; Lirong Wang; Brielle Schreiter; John S Lazo; Jurg Gertsch; Xiang-Qun Xie
Journal:  Int Immunopharmacol       Date:  2011-05-01       Impact factor: 4.932

8.  Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.

Authors:  Pietro Marini; Maria-Grazia Cascio; Angela King; Roger G Pertwee; Ruth A Ross
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

9.  Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.

Authors:  Alison E B Springs; Peer W F Karmaus; Robert B Crawford; Barbara L F Kaplan; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2008-09-12       Impact factor: 4.962

10.  N-acylethanolamine signaling in tobacco is mediated by a membrane-associated, high-affinity binding protein.

Authors:  Swati Tripathy; Kathryn Kleppinger-Sparace; Richard A Dixon; Kent D Chapman
Journal:  Plant Physiol       Date:  2003-04       Impact factor: 8.340

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.